Literature DB >> 20187324

Development of PARP inhibitors: an unfinished story.

Anand Patel1, Scott H Kaufmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20187324

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  5 in total

1.  Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Dorothea K Torous; Jeffrey C Bemis; Souk Phonethepswath; Carson Labash; Kristine Carlson; Jared Mereness; John Cottom; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

Review 2.  Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

Authors:  Yuan Yuan; Yu-Min Liao; Chung-Tsen Hsueh; Hamid R Mirshahidi
Journal:  J Hematol Oncol       Date:  2011-04-20       Impact factor: 17.388

3.  A single nucleotide variant of human PARP1 determines response to PARP inhibitors.

Authors:  Rivki Cashman; Alona Zilberberg; Avner Priel; Hagit Philip; Alexander Varvak; Avi Jacob; Irit Shoval; Sol Efroni
Journal:  NPJ Precis Oncol       Date:  2020-04-27

4.  Drug treatment of cancer cell lines: a way to select for cancer stem cells?

Authors:  Ilaria Chiodi; Cristina Belgiovine; Francesca Donà; A Ivana Scovassi; Chiara Mondello
Journal:  Cancers (Basel)       Date:  2011-03-04       Impact factor: 6.639

5.  Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.

Authors:  Wei Qiu; Robert Lam; Oleksandr Voytyuk; Vladimir Romanov; Roni Gordon; Simon Gebremeskel; Jakub Vodsedalek; Christine Thompson; Irina Beletskaya; Kevin P Battaile; Emil F Pai; Robert Rottapel; Nickolay Y Chirgadze
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.